Related by context. All words. (Click for frequent words.) 88 INxin 73 Phase #b/#a clinical 73 targeted radiotherapeutic 72 chronic thromboembolic pulmonary 72 Safinamide 72 phase IIb clinical 72 Cannabinor 72 MGd 71 systemic anaplastic large 71 CYT# potent vascular disrupting 71 Enzastaurin 70 selective modulator 70 fosbretabulin 70 recurrent glioblastoma multiforme 70 Cotara ® 70 Microplasmin 70 Phase IIb clinical trials 70 including eniluracil ADH 70 kidney urologic 70 novel VDA molecule 70 CB2 selective receptor agonist 70 multicenter Phase II 69 SYN# 69 oral prodrug 69 orally administered inhibitor 69 IL# PE#QQR 69 AGGRASTAT R Injection tirofiban 69 IAP inhibitor 69 thetreatment 69 brain metastases originating 69 sodium thiosulfate STS 69 essential thrombocythemia ET 68 Personalized Immunotherapy 68 BRIM2 68 catheter occlusion 68 Phase 2a clinical 68 Squalamine 68 selective androgen receptor modulator 68 Pimavanserin 68 investigational humanized monoclonal antibody 68 LHRH receptor positive 68 Genasense ® oblimersen 68 Phase 1b clinical trials 68 ELACYT 68 Curaxin CBLC# 68 investigational monoclonal antibody 68 polycythemia vera essential thrombocythemia 68 Combination REOLYSIN R 68 Deforolimus 68 hypoxia activated prodrug 68 Phase 2b Clinical Trial 68 Archexin 68 mGluR2 NAM 68 Trofex 68 Phase #b/#a trial 68 interferon alpha IFN 68 PNP inhibitor 68 huC# DM4 68 Aflibercept 67 R Saizen R 67 cannabinor 67 detect amyloid plaque 67 Omacetaxine 67 phase IIb trial 67 phase IIb study 67 Randomized Phase 67 Azedra 67 Randomized Double blind 67 Novel Oral 67 AAG geldanamycin analog 67 demonstrated antitumor activity 67 MAGE A3 ASCI 67 Solazed TM 67 small molecule activator 67 unresectable tumors 67 induced macular edema 67 essential thrombocythemia 67 acute peripheral arterial 67 CTAP# Capsules 67 dyskinesia PD LID 67 novel chimeric natriuretic 67 Enkephalin 67 Parathyroid hormone 67 Azedra TM 67 AEG# 67 complement inhibitor eculizumab 67 INCB# [003] 67 myelofibrosis polycythemia vera 67 aMCI precursor 67 IMA# 67 antibody MT# 67 accumulate preferentially 67 dexanabinol 67 Phase 1a clinical 67 edifoligide 67 medically refractory 67 ONCONASE R 67 Vicinium TM 67 polycythemia vera PV 67 pathological hallmark 67 MKC# MKC# PP 67 Brodmann Area 67 cetuximab Erbitux R 67 ThermoDox R 67 PEGylated Fab fragment 67 II Clinical Trial 67 triggers apoptosis programmed 67 phase IIa clinical 67 MTP inhibitor 67 FOLOTYN ® 67 Pivotal Phase III 67 Myelodysplastic Syndrome MDS 67 Xanafide 67 personalized cellular immunotherapy 67 Alzheimer disease cognitive impairment 67 Phase 2a Clinical Trial 67 GEM OS2 67 metastatic colorectal 67 Androxal TM 67 polysaccharide polymer 67 targeted nucleotide prodrug 67 Histone deacetylase 66 Degarelix 66 pan HDAC inhibitor 66 receptor tyrosine kinase inhibitor 66 Bezielle 66 PSMA ADC 66 fallopian tube cancers 66 mGluR5 negative 66 2 methoxyestradiol 66 carcinoma HCC 66 monoclonal antibody conjugated 66 papillary renal cell carcinoma 66 diagnostic biomarker 66 retinal vein occlusion induced 66 STRIDE PD 66 INS# [001] 66 selective antagonist 66 Preclinical Study 66 Meets Primary Endpoint 66 Phase Ib clinical trials 66 HP Acthar Gel repository 66 NPC 1C 66 Lisofylline LSF 66 IRX 2 66 brivaracetam 66 virus HCV protease inhibitor 66 alvespimycin 66 RezularTM 66 lomitapide 66 Ribavirin causes 66 benign prostatic hyperplasia enlarged 66 pancreatic colon 66 Angiocept 66 CEQ# 66 Oral Fingolimod 66 CDK inhibitor 66 OMP #R# 66 anti amnesic 66 Metastatic Melanoma 66 Proxinium TM 66 generation purine nucleoside 66 lenalidomide Revlimid R 66 mertansine 66 acute mania 66 SinuNase TM 66 PLX STROKE targeting 66 gefitinib Iressa 66 hyaluronidase enzyme 66 Panzem ® 66 ZFP TF 66 BrachySil ™ 66 R#/MEM # 66 Phase IIb III 66 liposomal formulation 66 MKC# MT 66 NMDA antagonist 66 Tesetaxel 66 haematologic 66 Diabetic Macular Edema DME 66 targets Galectin receptors 66 antibody MAb 66 mGluR5 NAM 66 teriflunomide 66 PDX pralatrexate 66 pharmacodynamic effects 66 transthyretin TTR mediated amyloidosis 66 doxorubicin Transdrug ® 66 DG# compounds targeting 66 Panzem R 66 LymphoStat B TM 66 Factor VIIa 66 SinuNase ™ 66 rALLy clinical trial 66 Zorbtive TM 66 generation antisense inhibitor 66 Achieves Primary Endpoint 66 Vascular Disrupting Agent 66 immune modulator 66 AQ4N 66 hyperoxaluria 66 recurrent metastatic 66 Lisofylline 66 fibrotic disease 66 midstage clinical 66 ExTRACT TIMI 66 TNF Tumor Necrosis Factor 66 CIMZIA TM certolizumab pegol 66 sorafenib tablets 66 2A receptor agonist 66 pediatric malignancies 66 Annamycin 66 Initiated Phase 66 relapsing remitting MS RRMS 66 PS# DARA 66 Seliciclib 66 hyperphenylalaninemia HPA due 66 Alfacell proprietary ribonuclease 66 Oral NKTR 65 vidofludimus 65 Solazed 65 protein tyrosine phosphatase 1B 65 Selective Electrochemical Tumor Ablation 65 Denufosol 65 NP2 Enkephalin 65 human IgG1 monoclonal 65 treat benign prostatic 65 uricase 65 TACI Ig 65 vivo validation 65 lintuzumab SGN 65 metastatic malignant 65 neuropathic pain spasticity 65 Tumour Vascular Disrupting Agent 65 relapsed MM 65 EVIZON TM 65 TRO# 65 hypervascular tumors 65 oral ghrelin agonist 65 evaluating tivozanib 65 Prospective Randomized 65 GRN# 65 diarrhea predominant irritable 65 ocular formulation 65 myeloid metaplasia 65 aurora kinase 65 refractory chronic lymphocytic 65 orthotopic model 65 TLK# 65 ospemifene 65 recurrent glioblastoma multiforme GBM 65 murine model 65 HGS ETR2 65 opioid induced bowel dysfunction 65 GAMMAGARD 65 formerly LymphoStat B 65 molecular imaging radiopharmaceutical 65 HDL Selective Delipidation 65 IMPACT DCM 65 PROSTASCINT R 65 vinca alkaloid 65 ZOLINZA 65 Occlusive Disease 65 pancreatic prostate 65 familial hypercholesterolemia FH 65 Aurora Kinase 65 Quinamed 65 MCSP respectively 65 Romidepsin 65 candidates Azedra TM 65 epithelial tumors 65 Glypromate 65 metaglidasen 65 targeted antifolate 65 PI3K/Akt pathway inhibitor 65 Empatic TM 65 GRNCM1 65 Zenvia ™ 65 dyslipidemia hypertension diabetes 65 bladder ovarian 65 acetonide FA 65 refractory acute myeloid 65 naturally occurring neuroprotective 65 RNAi therapeutic targeting 65 AVAPRO 65 intranasal formulation 65 recombinant tissue plasminogen 65 p# mitogen activated 65 TELINTRA R 65 orally inhaled migraine 65 advanced carcinoid 65 prokinetic agent 65 OncoGel 65 JAK inhibitor 65 Phase Ib study 65 Elagolix 65 Cerebril TM 65 acadesine 65 Leber Hereditary Optic Neuropathy 65 Phase Ib II 65 potent suppressor 65 oral ridaforolimus 65 MEND CABG II 65 occlusion PAO 65 mGluR2 positive 65 Phase IIB 65 Immunotherapeutic 65 corticosteroid dexamethasone 65 candidate CRLX# 65 cetuximab Erbitux 65 Sapacitabine 65 Cloretazine 65 Phase IIIb clinical 65 Corlux 65 ANG# 65 humanized interleukin 6 65 Initiate Clinical Trial 65 somatostatin analog 65 Spiegelmer ® 65 small molecule activators 65 forodesine 65 Hodgkin lymphoma HL 65 orally administered synthetic retinoid 65 Panzem R NCD 65 riociguat 65 PSN# [002] 65 selective phosphodiesterase 65 headache nasopharyngitis 65 Panzem NCD 65 hereditary emphysema 65 Ophena TM 65 either acutely decompensated 65 pertuzumab 65 rxRNA 65 Hepatocellular Carcinoma HCC 65 allosteric modulator NAM 65 receptor inhibitor 65 ALN TTR# 65 EGS# 65 PEG SN# 65 #beta HSD1 65 antiangiogenic agent 65 non nucleoside inhibitor 65 pathophysiological effects 65 myocardial infarction ventricular fibrillation 65 PEGylated anti 65 IIa trial 65 Ocrelizumab 65 Aplidin 65 Sudhir Agrawal D.Phil 64 recombinant PSMA vaccine 64 THR beta agonist 64 Novolimus 64 IMC #B 64 partial agonist 64 gemcitabine Gemzar ® 64 induce apoptosis programmed 64 Temsirolimus 64 ischemia induced 64 leukemia AML 64 rNAPc2 64 HCV NS5B polymerase 64 Phase IIb Trial 64 Vidaza azacitidine 64 Anti VEGF 64 Zemiva TM 64 Excellarate TM 64 verteporfin 64 CA4P 64 Hsp# Inhibitor 64 ASTEROID 64 modified glutathione analog 64 candidate XP# 64 Cutaneous T 64 novel synthetic peptide 64 Tasigna prolongs 64 histone deacetylase HDAC inhibitor 64 keloid scarring 64 Factor Receptor 64 Thiarabine 64 CBLC# 64 CCR9 64 GOUT 64 Philadelphia Chromosome Positive 64 metastatic neuroendocrine tumors 64 Exherin TM 64 Prodarsan R 64 Voreloxin 64 Factor VEGF 64 EDEMA3 trial 64 ADAMTS# 64 JAK1 64 Pivotal Clinical Trial 64 recurrent malignant glioma 64 Eculizumab 64 CA9 SCAN 64 unique alkylating agent 64 thalidomide Thalomid 64 Phase III Pivotal 64 Bucindolol 64 selective A1 adenosine 64 Cell Lymphoma 64 topically administered 64 INCB# [001] 64 MEND CABG 64 evaluating Actimmune 64 ZYBRESTAT fosbretabulin 64 candidate deforolimus 64 CD# CEA 64 plasma kallikrein inhibitor 64 Xcytrin R 64 dose escalation clinical 64 Phase 2a clinical trials 64 cMET 64 metastatic pancreatic 64 CARE HF 64 NS#/#A protease 64 Phase III Trial 64 malignant ascites 64 TOCOSOL Camptothecin 64 lexidronam injection 64 HGS ETR1 mapatumumab 64 individualized cellular immunotherapy 64 Vascugel 64 neovascularisation 64 GMX# 64 NU# direct 64 pioglitazone HCl 64 LymphoStat B belimumab 64 Phase 2b Study 64 overactive bladder AA# 64 RhuDex R 64 Phase Ib clinical 64 sitaxsentan 64 sarcoma melanoma 64 lung pancreatic 64 Polyneuropathy 64 FOLFOX6 chemotherapy regimen 64 Serostim ® 64 TBC# 64 ALN HPN 64 isoform selective 64 Cleviprex TM clevidipine 64 IMC A# 64 Intervention Effectiveness 64 p# inhibitor 64 compound AEZS 64 drug NP2 Enkephalin 64 Maximum Tolerated Dose MTD 64 QLT# 64 Zybrestat 64 alpha1 antitrypsin deficiency 64 sunitinib Sutent 64 HuMax EGFr 64 radiation sensitizer 64 JZP 64 deforolimus 64 OHR/AVR# 64 GLPG# 64 irreversible inhibitor 64 MEK inhibitor 64 sapacitabine CYC# 64 Prednisone Against Refractory 64 VA# [002] 64 CYP#A# CYP#D# 64 Initiate Phase 64 VNP#M 64 Dosa suffers 64 IMiDs R 64 Lixivaptan 64 oral picoplatin 64 Phase #/#a trial 64 Amgen Neulasta R 64 acyclovir Lauriad R 64 treat chronic sinusitis 64 apoptosis proteins 64 intravascular hemolysis 64 MEK inhibitor RDEA# 64 ATRA IV 64 proprietary polysaccharide 64 steroid refractory 64 Naive Patients 64 idiopathic thrombocytopenic purpura ITP 64 Parkinson disease levodopa induced 64 radiolabeled TM# 64 vapreotide acetate 64 gastro intestinal inflammation 64 ENMD # 64 BrachySil TM 64 EndoTAG TM -1 64 TNFerade TM 64 rhIGF-I/rhIGFBP-3 64 SPRYCEL ® 64 phase IIb 64 epithelial ovarian 64 Cetrorelix 64 compound perifosine 64 Tramiprosate ALZHEMED TM 64 ATL# [001] 64 Pathway Inhibitor 64 romidepsin novel 64 Syncria R 64 therapeutic monoclonal antibody 64 investigational immunotherapy 64 AA Amyloidosis 64 depsipeptide 64 Tyrosine Kinase Inhibitor 64 gonadotropin releasing hormone GnRH 64 neurologic progression 64 chronic myeloid 64 CCR9 antagonist 64 drug GAP #B# 64 dextofisopam 64 alpha folate receptor 64 Exelixis compounds 64 Phase III Clinical Trial 64 TG# [003] 64 Pegloticase 64 randomized Phase IIb 64 Onconase 64 class anticancer quinolone 64 XP# XP# 64 VEGFR2 inhibitor 64 XL# anticancer compounds 64 rusalatide acetate 64 Troxatyl 64 dose escalation Phase 64 DDP# 64 Granulocyte Colony Stimulating Factor 64 YONDELIS 64 denileukin diftitox 64 Myolimus 64 Zemiva ™ 64 pan histone deacetylase 64 steroid refractory ulcerative 64 pralatrexate injection folate analogue 64 Primary Hypercholesterolemia 64 cytopenias 64 opioid naive 64 oral Janus kinase 64 non splenectomized 64 pain palliation 64 vaso occlusive crisis 64 TELINTRA 64 SUCCEED trial 64 next generation URAT1 64 Vidaza ® 64 topoisomerase II inhibitor 64 landmark ATHENA 64 PDE# inhibitors 64 Ophena 63 Tezampanel 63 placebo controlled clinical 63 Begins Dosing 63 endothelin antagonists 63 methylnaltrexone bromide 63 Dose Escalation 63 sodium glucose cotransporter 63 taxane resistant 63 derivatives Radilex TM 63 erlotinib Tarceva ® 63 Familial Adenomatous Polyposis FAP 63 Diffuse Large B 63 Phase Ib Clinical Trial 63 cutaneous T 63 class mGluR5 inhibitor 63 Alocrest 63 immunomodulatory therapy 63 INSPIRE Trial Phase III 63 pseudobulbar affect PBA 63 neuronal nitric oxide synthase 63 Orally administered 63 Anavex #-# 63 ThermoDox ® clinical 63 Guanilib 63 QuadraSphere 63 Diabetic Neuropathy 63 Transdrug ® nanoparticle 63 NOX E# 63 AFREZZA TM 63 Inosine 63 Tumor Response 63 tiapamil 63 davunetide intranasal AL 63 multicenter randomized placebo controlled 63 Patients Treated With 63 Pharmacokinetics PK 63 Tolvaptan 63 anti fibrotic 63 Ischemic 63 induced mucositis 63 Acute myeloid leukemia AML 63 ON #.Na 63 RAV# 63 Phase IIIb 63 PKC# 63 Interferon beta 63 Heterozygous Familial Hypercholesterolemia 63 plus DOXIL 63 cardiac dysfunction 63 TRIOLEX HE# APOPTONE HE# 63 BCG refractory carcinoma 63 Glioblastoma multiforme 63 Pivotal Trial 63 5 HT4 63 ALN PCS 63 interferon beta 1a infertility 63 Study Evaluating 63 hypoxia selective 63 Aplidin R 63 dopamine D2 63 humanized therapeutic 63 rosuvastatin #mg 63 Crohn disease CD 63 humanised monoclonal antibody 63 TRAIL R1 63 hepatocellular carcinoma liver 63 anemia thrombocytopenia 63 induces apoptosis 63 Alfimeprase 63 Phase 2b clinical trials 63 pharmacokinetic PK study 63 Liposomal 63 RCW breast cancer 63 MVA MUC1 IL2 63 SAR# [002] 63 Phase 2b Trial 63 systemic RNAi therapeutic 63 ruxolitinib 63 RhuDex ® 63 topically applied SEPA 63 vitreoretinal disorders 63 Chemophase 63 multi kinase inhibitor 63 allogeneic HSCT 63 EXPAREL TM 63 hypercholesterolemic patients 63 prospective multicenter study 63 Myocet 63 schizophrenia CIAS 63 seliciclib CYC# 63 Vitaxin 63 ischemia reperfusion 63 Antitumor Activity 63 tezampanel NGX# 63 5 fluorouracil leucovorin 63 oral nucleoside analogue 63 GORE TAG Device 63 dasatinib Sprycel ® 63 gastrointestinal mucositis 63 highly selective inhibitor 63 Phase IIb trials 63 ALB # 63 cell lymphoma CTCL 63 CXB# 63 Sipuleucel T 63 GW# [003] 63 anticancer compound 63 Glufosfamide 63 Endologix Powerlink System 63 Initiates Phase II 63 p# MAP kinase inhibitor 63 Cx# [002] 63 docetaxel Taxotere ® 63 PAOD 63 cardio renal 63 MAP# 63 tubulin inhibitor 63 Sym# 63 immunotherapeutic agent 63 small molecule agonists 63 EDEMA3 63 NeoLipid R 63 occlusion CRVO 63 vitreous floaters 63 Tyrima 63 Acute Ischemic Stroke 63 histone deacetylase HDAC 63 Initiates Enrollment 63 Fibrin Pad 63 albiglutide 63 trastuzumab DM1 T DM1 63 Brentuximab Vedotin SGN 63 galiximab 63 assessing T DM1 63 severe oral mucositis 63 CRLX# 63 Empatic ™ 63 HDAC Inhibitor 63 brivanib 63 Morquio 63 pulmonary metastasis 63 CIMZIA ™ 63 Fx #A 63 orally bioavailable 63 MKC# 63 varespladib 63 GVAX ® 63 familial amyloidotic polyneuropathy FAP 63 epithelial origin 63 aerosolized KL4 surfactant 63 mTOR mammalian target 63 Kinoid 63 intracoronary 63 pharmacological chaperone 63 systemic amyloidosis 63 CDK cyclin dependent 63 ALN VSP Phase 63 histone deacetylase 63 lucinactant 63 vitro pharmacology 63 dependent kinase inhibitor 63 glioblastoma multiforme GBM 63 Natalizumab 63 small molecule tyrosine 63 CINTREDEKIN BESUDOTOX 63 Wafer polifeprosan 63 potent antiproliferative 63 PrevOnco ™ 63 CTAP# 63 endothelial activation 63 OncoVex 63 polyneuropathy HIV DSP 63 Transdermal Patch 63 ALN TTR 63 antiproliferative effects 63 KRN# 63 dexpramipexole 63 inhaled formulation 63 endothelin receptor 63 Methylnaltrexone 63 Adenoscan R 63 SNT MC# 63 beta 1a 63 Traficet EN 63 cleavable linker 63 indolent follicular non 63 budesonide foam 63 PRT# 63 Neo Bladder Augment 63 Motesanib 63 NASH Huntington 63 crizotinib PF # 63 oral rivaroxaban 63 MT#/MEDI-# 63 ESBA# 63 Chrysalin 63 Completes Patient Enrollment 63 Resten NG 63 fibrin deposition 63 Dapagliflozin 63 bile duct tumor 63 Albuferon TM 63 INTEGRILIN ® 63 adult mesenchymal stem 63 Ovitrelle R Serostim 63 peritumoral brain edema 63 esophageal gastric 63 MYDICAR ® 63 MEK Inhibitor 63 Mipomersen 63 occlusive disease 63 genomic biomarker 63 iobenguane 63 PI3K/mTOR 63 omega interferon 63 Ad5FGF 4 63 M# rationally 63 ® bortezomib 63 FUSILEV enhances 63 neurogenic bladder 63 Central Retinal Vein 63 malignant pheochromocytoma 63 ductal adenocarcinoma 63 BRIM3 63 ANCA associated 63 Fulvestrant 63 synovial tissue 63 Controlled Trial 63 Biolimus A9 63 NV1FGF 63 refractory gout 63 delivery polymer matrix 63 ProSavin 63 cediranib 63 NeuroSTAT ® 63 placebo controlled Phase 63 humanised antibody 63 mediated inhibition 63 hypertrichosis occurred 63 receptor partial agonist 63 RhuDex 63 cilengitide 63 brand ciclesonide HFA 63 Refractory Hodgkin Lymphoma 63 Pulmonary Arterial Hypertension PAH 63 lymphomas leukemias 63 chronic myocardial ischemia 63 gamma secretase inhibitor 63 triggers apoptosis 63 ixabepilone 63 Pivotal Phase 63 evaluating picoplatin 63 Dose Ranging Study 63 oral deforolimus 63 Bayer HealthCare Onyx Pharmaceuticals 63 PRX# 63 rheumatoid arthritis osteoarthritis ankylosing 63 angiotensin analog 63 HDL Mimetic Peptide 63 MyoCell SDF 1 63 immunotoxin 63 Duodenal 63 Homspera TM 63 choroidal vasculopathy 63 lorvotuzumab mertansine 63 cerebral vasospasm 63 Teriflunomide 63 refractory prostate cancer 63 dirucotide MBP# 63 CHAMPION PCI 63 Upregulation 63 intravesical infusion therapy 63 chemopreventive agent 63 adipose stem 63 tolerability pharmacokinetics 63 Parathyroid Hormone 63 Genasense ® 63 mda 7 63 Telik logo TELINTRA 63 ILUVIEN ® 63 midstage clinical trials 63 Kamada AAT 63 BRAF inhibitor 63 PLX MS 63 benign prostatic hypertrophy BPH 63 Catena ® 63 NAGS deficiency 63 SNT-MC#/idebenone 63 Overactive Bladder OAB 63 eosinophilic asthma 63 Friedreich Ataxia FRDA 63 MELAS 63 5 HT2A serotonin 63 luteinizing hormone releasing 63 Zarnestra 63 Onalta ™ 63 EGFR TKI 62 alpha GAL 62 triphendiol 62 phase IIa 62 factor Xa 62 biliary tract cancer 62 Platelet Inhibition 62 selective kinase inhibitor 62 enhance ApoA 62 delivers fluocinolone acetonide FA 62 metastatic castration resistant 62 tafamidis 62 bleeding pallor 62 cell adhesion molecule 62 Phase 2a Trial 62 PANVAC VF 62 PD LID 62 ACV1 62 Systemic lupus erythematosus 62 oxypurinol 62 Eprodisate 62 Protein Kinase C 62 basal bolus regimen 62 EFAPROXYN 62 Pyridorin 62 Matrix Phase 2b 62 Clolar ® 62 oral isoform selective HDAC 62 Akt inhibitor 62 vasculopathy 62 idiopathic thrombocytopenic purpura 62 telomerase inhibitor drug 62 morphometric vertebral fractures 62 orally dosed 62 adenomatous 62 novel nucleoside analog 62 corticotropin injection 62 RhuDex TM 62 sunitinib Sutent ® 62 ToGA 62 multicenter Phase 62 Gleevec resistant 62 epoetin alpha 62 Perceiva 62 incyclinide 62 Angiotensin Converting Enzyme 62 pathological hallmarks 62 HGS ETR1 62 immuno modulatory 62 recurrent metastatic ovarian cancer 62 Glioblastoma Multiforme 62 Myelofibrosis 62 macular edema secondary 62 Romiplostim 62 selective inverse agonist 62 orally inhaled 62 chronic idiopathic thrombocytopenic purpura 62 5 HT6 receptor 62 IIa trials 62 histone deacetylase inhibitor 62 sd rxRNA 62 selective agonist 62 bevacizumab Avastin ® 62 sorafenib Nexavar 62 Phase IIa trial 62 Phase Ib IIa 62 Mg Usa 62 LAB CGRP 62 Replacement Therapy 62 norepinephrine reuptake inhibitor 62 Augment TM 62 Drug Candidate 62 compound INCB# 62 Lu AA# 62 downregulates 62 randomized blinded 62 SUTENT ® 62 tumor necrosis 62 agent VDA 62 Panzem 62 Ph + acute lymphoblastic 62 octreotide implant 62 BZL# 62 Glioma 62 vascular disrupting agent 62 Prodarsan ® 62 ANCHOR trial 62 engineered anticoagulant 62 PORxin TM 62 enkephalin 62 P#Y# [001] 62 indibulin 62 peptidic compound 62 metastatic liver 62 efaproxiral 62 Elestrin ® 62 IV Busulfex 62 Proellex TM 62 Subarachnoid hemorrhage 62 allosteric modulator PAM 62 antisense inhibitors 62 pharmacodynamic profile 62 sulfonylhydrazine class 62 Phase IIb Clinical Trial 62 humanized monoclonal 62 neratinib 62 CINQUIL 62 Generx ™ 62 relapsed leukemia 62 paraneoplastic 62 plasma pharmacokinetics 62 busulfan 62 Leukemias 62 Val HeFT 62 receiving chemoradiation therapy 62 GRNOPC1 contains 62 ® natalizumab 62 non alcoholic steatohepatitis 62 tumors GIST 62 Trandolapril 62 Acute Exacerbations 62 cortisol synthesis 62 Atiprimod 62 novel topoisomerase 62 ralfinamide 62 potent inducer 62 cetrorelix pamoate 62 Epratuzumab 62 Preclinical studies suggest 62 inhibit oxidative stress 62 oral dual endothelin 62 VAPRISOL 62 TRIOLEX HE# 62 thymoma 62 HCV protease 62 treating cancerous tumors 62 Pralatrexate 62 drug zotarolimus 62 kinase inhibition 62 SGLT2 62 peripheral arterial occlusive disease 62 weekly subcutaneous injections 62 orally bioavailable mimics 62 gonadotrophin releasing hormone 62 antiangiogenic therapy 62 neuroinflammatory 62 PORxin TM platforms 62 NAVISTAR R 62 florbetaben 62 D aspartate NMDA receptor 62 neovascular diseases 62 abnormal p#